Skip to content

Study · Animal study (in vivo) · mouse · 2013

9 results

NAP (davunetide) modifies disease progression in a mouse model of severe neurodegeneration: protection against impairments in axonal transport.

Jouroukhin Y, Ostritsky R, Assaf Y, Pelled G, Giladi E, Gozes I

Neurobiology of disease28 Apr 2013Cited by 93 (Europe PMC)

PMID23631872 (opens in a new tab)DOI10.1016/j.nbd.2013.04.012 (opens in a new tab)PepBankPUB-23631872
Publisher pagePubMedAsk about this study
Jump to 9 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study9

9 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In ALS mice, acute NAP treatment normalized axonal transport rates.

    In plain wordsIn mice with an ALS model, acute NAP treatment restored axonal transport rates to normal.

    Peptide
    Davunetide
    Outcome
    IncreaseAxonal transport rates
    Study

    mousen: not reported in source

    SOD1-G93A ALS model
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Acute NAP treatment normalized axonal transport rates in these ALS mice.
    1 context sentence
    Summary · context
    To evaluate, for the first time, the impact of NAP on axonal transport in vivo and to translate it to neuroprotection in a severe neurodegeneration, the SOD1-G93A mouse model for amyotrophic lateral sclerosis (ALS) was used.
  2. 02AnimalAnimal study (in vivo)Mechanism

    In ALS mice, chronic NAP treatment significantly reduced brain tau hyperphosphorylation.

    In plain wordsIn mice with an ALS model, chronic NAP treatment reduced abnormal tau phosphorylation in the brain.

    Peptide
    Davunetide
    Outcome
    DecreaseTau hyperphosphorylation
    Study

    mousen: not reported in source

    SOD1-G93A ALS model
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Tau hyperphosphorylation, associated with MT dysfunction and defective axonal transport, was discovered in the brains of the ALS mice and was significantly reduced by chronic NAP treatment.
    1 context sentence
    Summary · context
    To evaluate, for the first time, the impact of NAP on axonal transport in vivo and to translate it to neuroprotection in a severe neurodegeneration, the SOD1-G93A mouse model for amyotrophic lateral sclerosis (ALS) was used.
  3. 03AnimalAnimal study (in vivo)Efficacy outcome

    In wild type mice, NAP reversed colchicine-induced axonal transport disruption.

    In plain wordsIn wild type mice, NAP reversed axonal transport problems caused by colchicine.

    Peptide
    Davunetide
    Outcome
    DecreaseColchicine-induced axonal transport disruption
    Study

    mousen: not reported in source

    healthy wild type mice exposed to colchicine
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Furthermore, in healthy wild type (WT) mice, NAP reversed axonal transport disruption by colchicine, suggesting drug-dependent protection against axonal transport impairment through stabilization of the neuronal MT network.
    1 context sentence
    Summary · context
    To evaluate, for the first time, the impact of NAP on axonal transport in vivo and to translate it to neuroprotection in a severe neurodegeneration, the SOD1-G93A mouse model for amyotrophic lateral sclerosis (ALS) was used.
  4. 04AnimalAnimal study (in vivo)Efficacy outcome

    In ALS mice, chronic NAP treatment significantly protected spinal cord motor neurons against ALS-like pathology.

    In plain wordsIn mice with an ALS model, chronic NAP treatment protected spinal cord motor neurons from disease-like damage.

    Peptide
    Davunetide
    Outcome
    DecreaseSpinal cord motor neuron pathology
    Study

    mousen: not reported in source

    SOD1-G93A ALS model
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Histochemical analysis showed that chronic NAP treatment significantly protected spinal cord motor neurons against ALS-like pathology.
    1 context sentence
    Summary · context
    To evaluate, for the first time, the impact of NAP on axonal transport in vivo and to translate it to neuroprotection in a severe neurodegeneration, the SOD1-G93A mouse model for amyotrophic lateral sclerosis (ALS) was used.
  5. 05AnimalAnimal study (in vivo)Efficacy outcome

    In SOD1-G93A mice, chronic daily NAP delayed trigeminal motor nucleus degeneration, significantly apparent at days 90-100.

    In plain wordsIn mice with an ALS model, daily NAP delayed degeneration of the trigeminal motor nucleus.

    Peptide
    Davunetide
    Outcome
    DecreaseTrigeminal motor nucleus degeneration
    Study

    mousen: not reported in source

    SOD1-G93A ALS model
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Chronic daily NAP treatment of the SOD1-G93A mice, initiated close to disease onset, delayed degeneration of the trigeminal, facial and hypoglossal motor nuclei as was significantly apparent at days 90-100 and further protected the VTA throughout life.
    1 context sentence
    Summary · context
    To evaluate, for the first time, the impact of NAP on axonal transport in vivo and to translate it to neuroprotection in a severe neurodegeneration, the SOD1-G93A mouse model for amyotrophic lateral sclerosis (ALS) was used.
  6. 06AnimalAnimal study (in vivo)Efficacy outcome

    In SOD1-G93A mice, chronic daily NAP delayed facial motor nucleus degeneration, significantly apparent at days 90-100.

    In plain wordsIn mice with an ALS model, daily NAP delayed degeneration of the facial motor nucleus.

    Peptide
    Davunetide
    Outcome
    DecreaseFacial motor nucleus degeneration
    Study

    mousen: not reported in source

    SOD1-G93A ALS model
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Chronic daily NAP treatment of the SOD1-G93A mice, initiated close to disease onset, delayed degeneration of the trigeminal, facial and hypoglossal motor nuclei as was significantly apparent at days 90-100 and further protected the VTA throughout life.
    1 context sentence
    Summary · context
    To evaluate, for the first time, the impact of NAP on axonal transport in vivo and to translate it to neuroprotection in a severe neurodegeneration, the SOD1-G93A mouse model for amyotrophic lateral sclerosis (ALS) was used.
  7. 07AnimalAnimal study (in vivo)Efficacy outcome

    In SOD1-G93A mice, chronic daily NAP delayed hypoglossal motor nucleus degeneration, significantly apparent at days 90-100.

    In plain wordsIn mice with an ALS model, daily NAP delayed degeneration of the hypoglossal motor nucleus.

    Peptide
    Davunetide
    Outcome
    DecreaseHypoglossal motor nucleus degeneration
    Study

    mousen: not reported in source

    SOD1-G93A ALS model
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Chronic daily NAP treatment of the SOD1-G93A mice, initiated close to disease onset, delayed degeneration of the trigeminal, facial and hypoglossal motor nuclei as was significantly apparent at days 90-100 and further protected the VTA throughout life.
    1 context sentence
    Summary · context
    To evaluate, for the first time, the impact of NAP on axonal transport in vivo and to translate it to neuroprotection in a severe neurodegeneration, the SOD1-G93A mouse model for amyotrophic lateral sclerosis (ALS) was used.
  8. 08AnimalAnimal study (in vivo)Efficacy outcome

    In SOD1-G93A mice, chronic daily NAP protected the ventral tegmental area throughout life.

    In plain wordsIn mice with an ALS model, daily NAP protected the ventral tegmental area throughout life.

    Peptide
    Davunetide
    Outcome
    IncreaseVentral tegmental area protection
    Study

    mousen: not reported in source

    SOD1-G93A ALS model
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Chronic daily NAP treatment of the SOD1-G93A mice, initiated close to disease onset, delayed degeneration of the trigeminal, facial and hypoglossal motor nuclei as was significantly apparent at days 90-100 and further protected the VTA throughout life.
    1 context sentence
    Summary · context
    To evaluate, for the first time, the impact of NAP on axonal transport in vivo and to translate it to neuroprotection in a severe neurodegeneration, the SOD1-G93A mouse model for amyotrophic lateral sclerosis (ALS) was used.
  9. 09AnimalAnimal study (in vivo)Efficacy outcome

    In ALS mice, NAP treatment significantly prolonged life span.

    In plain wordsIn mice with an ALS model, NAP treatment increased life span.

    Peptide
    Davunetide
    Outcome
    IncreaseLife span
    Study

    mousen: not reported in source

    SOD1-G93A ALS model
    Outcome group
    Mortality · Whole body
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Importantly, protection of the VTA was significantly correlated with longevity and overall, NAP treatment significantly prolonged life span in the ALS mice.
    1 context sentence
    Summary · context
    To evaluate, for the first time, the impact of NAP on axonal transport in vivo and to translate it to neuroprotection in a severe neurodegeneration, the SOD1-G93A mouse model for amyotrophic lateral sclerosis (ALS) was used.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    27 Oct 2026, 18:20 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:32 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.